Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
Pfizer, Novartis, and Shire are among nearly a dozen biopharma companies, research institutions, and developers building a combined 3.5 million plus square feet of lab and office space totaling more than $2 billion across Massachusetts. The list also includes research institutions like Broad Institute and developers like Alexandria Real Estate Equities. While companies are growing, with aided incentives like tax breaks, Massachusetts will face increasing competition from global emerging markets with their own incentives such as lower wages and less regulatory red tape.